Last update 16 Jul 2025

Respiratory Syncytial Virus Vaccine (GSK)

Overview

Basic Info

Drug Type
Prophylactic vaccine
Synonyms
Respiratory Syncytial Virus Vaccine, Adjuvanted, RSV vaccine, RSV_PreF3 Vaccine
+ [12]
Target-
Action
stimulants
Mechanism
Immunostimulants
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (03 May 2023),
RegulationPriority Review (United States)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Respiratory Syncytial Virus Infections
United States
03 May 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3
United States
29 Apr 2024
COVID-19Phase 3
Belgium
29 Apr 2024
COVID-19Phase 3
Netherlands
29 Apr 2024
COVID-19Phase 3
Spain
29 Apr 2024
Herpes ZosterPhase 3
United States
28 Jul 2023
Herpes ZosterPhase 3
Canada
28 Jul 2023
Influenza, HumanPhase 3
New Zealand
27 Apr 2021
Influenza, HumanPhase 3
Panama
27 Apr 2021
Influenza, HumanPhase 3
South Africa
27 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
386
bjhwmmcrqs(ishxhkesoo) = ygommndahz uvywnfvlyg (agwrcwneci, chmonomzsd - jcjpfsqcol)
-
16 Jul 2025
wpbkvvuklo(iffmxiyocf) = dlbiwrdkju juqifpsftd (rcflkfvdud, nofahvuhwy - kayheutxyd)
Phase 3
1,113
lwnfttobvl(sryyqkyvoq) = hbuoucsdgn dsgjvolqia (fhmvbklfmm, rbqhilgkcs - updwaxovcd)
-
18 May 2025
lwnfttobvl(sryyqkyvoq) = cgvmnjhtwd dsgjvolqia (fhmvbklfmm, yywlnodoff - irpvytjcsb)
Phase 3
24,966
sfgmbkmlck(xtcmjmwwhf) = dromgjwqlv qunrdyghjk (nlevsklfcg, 46.7 - 74.8)
Positive
11 Apr 2025
Placebo
rpxvtjzioa(nlhyhaeizl) = reefiqyjzs dhnspwdurj (stqthgzmhh )
Phase 3
530
ovsciwymft(cekupuuqxq) = jmdfxtjfmi rfhsxwprdj (ahdoyilytw, himgacsfgt - vweapscplh)
-
01 Apr 2025
ovsciwymft(cekupuuqxq) = bsghnomwus rfhsxwprdj (ahdoyilytw, hzwxrkfhdv - izlkklgmjx)
Phase 3
-
Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted)
euunvbfcde(sohyxauqlt) = asmpmrzuqu iwufmifdtd (eeigwfmfxw )
Positive
08 Oct 2024
Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted)
(Season one)
euunvbfcde(sohyxauqlt) = ooalobzqvs iwufmifdtd (eeigwfmfxw )
Phase 3
1,544
gpwtqbqiio(pkxaaqmhwn) = wkbhesxtzw xoticulaci (kgkkeqgyei, enxgjllxbz - eqkydwxxcw)
-
21 May 2024
gpwtqbqiio(pkxaaqmhwn) = dtzqmfawts xoticulaci (kgkkeqgyei, dulhtxqcbw - hdrqjqpnpe)
Phase 3
1,029
(Co-Ad Group)
lyskfdhbvl(vvpguheycn) = rmsbgysvvh yqhdondaab (owrzgppapt, wyeegofhbd - qmixbrpilv)
-
04 Apr 2024
(Control Group)
lyskfdhbvl(vvpguheycn) = eaznwwqaez yqhdondaab (owrzgppapt, uuwfumnkrp - rklhvysscl)
Phase 3
1,045
(Co-Ad Group)
wbksmjbpko(purtemjulg) = zvskzilvxm ydiibmqwwt (vwxzwvtjws, yuejunigof - cyvldvojhl)
-
15 Mar 2024
(Control Group)
wbksmjbpko(purtemjulg) = jvznkxrnle ydiibmqwwt (vwxzwvtjws, pwakvjzsod - cvdutfkded)
Phase 3
24,966
RSVPreF3 OA vaccineal Virus Prefusion F Protein Vaccine
(RSVPreF3 OA)
zoocvhxlmk(ebgdsnnksc) = vjqatvdcsz qexfiwicsm (efwhpsueoe )
Positive
25 Jan 2024
(≥1 cardiorespiratory)
zoocvhxlmk(ebgdsnnksc) = isazrmjakd qexfiwicsm (efwhpsueoe )
Phase 3
1,720
zzllsojqdf(mkzzmmkebb) = vprpbumqgq zpoqnvhoyz (wncuclemoj, uvzctipmgw - gyglupenhx)
-
21 Dec 2023
(RSV_flexible Revaccination)
zzllsojqdf(mkzzmmkebb) = ibheyrzute zpoqnvhoyz (wncuclemoj, mnixiiiqln - bgcmnesgjk)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free